Optimer Pharmaceuticals to Webcast Investor and Analyst Reception on December 5th


SAN DIEGO, Nov. 28, 2011  /PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) will host investors and analysts in New York City on December 5, 2011 for a corporate overview and update with a focus on its commercial strategy and launch of DIFICID.  A live webcast of the event will begin at 8:30 a.m. Eastern time and will be accessible on the Investors page of the Company's website at www.optimerpharma.com. A replay will be available for 90 days.

(Logo: http://photos.prnewswire.com/prnh/20090413/LA97352LOGO)

Speakers will include members of the executive management team as well as guest speaker Roy F. Chemaly, M.D., MPH, University of Texas MD Anderson Cancer Center.

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a global biopharmaceutical company focused on discovering, developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer has developed and is commercializing DIFICID™ (fidaxomicin) tablets, an FDA-approved antibacterial drug for the treatment of adult patients with Clostridium difficile-associated diarrhea (CDAD). Optimer is seeking marketing authorization for fidaxomicin in the European Union and Canada and is exploring marketing authorization in other parts of the world where C. difficile has emerged as a serious health problem, including Asia. Additional information can be found at http://www.optimerpharma.com.


Optimer Pharmaceuticals, Inc.
David Walsey, VP of Investor Relations and Corporate Communications

Canale Communications
Jason I. Spark, Senior Vice President


SOURCE Optimer Pharmaceuticals, Inc.

Suggested Articles

A suspected cancer-causing impurity that has been found in some blood pressure medicines has now shown up in Zantac and some OTC antacids.

Roche is steamrolling with Ocrevus, and to maintain that lead, its touting long-term data that show the earlier it’s given, the better patients do.

New data shows a significant reduction in relapse rates in patients taking Novartis' repurposed cancer drug ofatumumab.